0001145197FALSE00011451972026-11-192026-11-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2026
INSULET CORPORATION
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
| Delaware | | 001-33462 | | 04-3523891 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | | | | | | | | | | | |
| 100 Nagog Park | |
| Acton | Massachusetts | 01720 | |
| (Address of principal executive offices) | (Zip Code) | |
| | | | | | | | | | | | | | |
| Registrant’s telephone number, including area code: | (978) | 600-7000 | |
| | | | | | | | | | | | | | |
| Not Applicable (Former name or former address, if changed since last report) | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | | | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | | | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | | | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| | | | | |
| Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, $0.001 Par Value Per Share
| | PODD | | The NASDAQ Stock Market, LLC
|
| | | | | |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On November 19, 2026, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Michael R. Minogue to the Board, effective November 20, 2026. Mr. Minogue previously served on the Board as a Class I director from August 2017 until September 2026, when he resigned to focus on his candidacy for Governor of Massachusetts. Mr. Minogue will again serve as a Class I director, with a term expiring at the Company’s 2029 Annual Meeting of Stockholders.
Mr. Minogue is the President and CEO of Minogue Consulting, LLC and Heartwork Capital, LLC, providing services for executive teams, boards and college students through leadership development programs, speaking engagements and one-on-one mentoring and investing in companies elevating the standard of care in medicine. From 2004 until its sale in December 2022, Mr. Minogue served as Chairman of the Board, President and Chief Executive Officer of Abiomed, Inc., a global leader in healthcare technology and innovation. Prior to joining Abiomed, he spent 11 years with General Electric Healthcare, where he held numerous leadership roles and holds three patents. Mr. Minogue served as a director of the Advanced Medical Technology Association (AdvaMed), a medical device industry association, from 2007 to 2023, serving as Chairman from 2021 to 2023. In addition, he has served on the Boards of Directors of LifeCell, Bioventus and the Medical Device Innovation Consortium (MDIC) and as Chairman of the Governor’s Advisory Council on Veterans’ Services for the Commonwealth of Massachusetts. Mr. Minogue cofounded and is a director of the Mike and Renee Minogue Foundation and MedTechVets, a 501(c)(3) nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the medtech industry. Mr. Minogue served as an officer in the U.S. Army, receiving multiple distinctions, including Airborne, Ranger, Desert Storm veteran and a Bronze Star. He received a Bachelor of Science in Engineering Management from the United States Military Academy at West Point and an MBA from the University of Chicago Graduate School of Business.
There are no arrangements or understandings between Mr. Minogue and any other persons pursuant to which he was selected as a director. There are no transactions involving Mr. Minogue required to be disclosed pursuant to Item 404(a) of Regulation S-K. As non-employee directors of the Company, Mr. Minogue will receive an initial grant of restricted stock units having a grant date fair value of approximately $121,700, representing the pro-rated value of the $260,000 annual equity award under the Company’s non-employee director compensation program. He will also receive cash compensation under that program, as described in the “Non-Employee Director Compensation” section of the Company's proxy statement filed with the Securities and Exchange Commission on April 6, 2026, as may be amended by the Board from time to time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | | | | | | | |
| | | | | |
| | | | INSULET CORPORATION |
| | | |
| November 20, 2026 | | | | By: | /s/ John W. Kapples |
| | | | Name: | John W. Kapples |
| | | | Title: | Senior Vice President and General Counsel |